378 related articles for article (PubMed ID: 18030581)
21. Clinical significance of serial measurement of the serum levels of soluble interleukin-2 receptor and soluble CD8 in malignant lymphoma.
Motokura T; Kobayashi Y; Fujita A; Nakamura Y; Taniguchi T; Uchimaru K; Asano S
Leuk Lymphoma; 1995 Jan; 16(3-4):355-62. PubMed ID: 7719243
[TBL] [Abstract][Full Text] [Related]
22. [The serum levels of soluble interleukin-2 receptor in patients with malignant lymphocytic proliferative disorders].
Xu J; Wang B
Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):82-4. PubMed ID: 10921108
[TBL] [Abstract][Full Text] [Related]
23. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement.
Thi Hong Nguyen C; Kambe N; Kishimoto I; Ueda-Hayakawa I; Okamoto H
J Dermatol; 2017 Jul; 44(7):789-797. PubMed ID: 28295528
[TBL] [Abstract][Full Text] [Related]
24. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
25. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pavlidis AN; Kalef-Ezra J; Bourantas LC; Lambrou A; Mavridis A
Int J Biol Markers; 1993; 8(1):14-20. PubMed ID: 8496627
[TBL] [Abstract][Full Text] [Related]
26. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease.
Devizzi L; Maffioli L; Bonfante V; Viviani S; Balzarini L; Gasparini M; Valagussa P; Bombardieri E; Santoro A; Bonadonna G
Ann Oncol; 1997; 8 Suppl 1():53-6. PubMed ID: 9187430
[TBL] [Abstract][Full Text] [Related]
27. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis.
Kalkanis A; Kalkanis D; Drougas D; Vavougios GD; Datseris I; Judson MA; Georgiou E
Nucl Med Commun; 2016 Mar; 37(3):273-7. PubMed ID: 26544095
[TBL] [Abstract][Full Text] [Related]
28. Soluble interleukin-2 receptor levels in patients with non-Hodgkin's lymphoma or with acute leukemia.
Chang CS; Lin SF; Liu HW
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1988 May; 21(2):79-84. PubMed ID: 3264231
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of residual mediastinal-hilar Ga-67 uptake after treatment for Hodgkin's and non-Hodgkin's lymphomas: what degree of Ga-67 uptake is significant?
Nikpoor N; Aliabadi P; Diaz L; Mannting F
Clin Nucl Med; 2000 Dec; 25(12):959-62. PubMed ID: 11129161
[TBL] [Abstract][Full Text] [Related]
30. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani L; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Venditti A; Del Poeta G; Cantonetti M
Eur J Haematol; 1995 Jan; 54(1):9-17. PubMed ID: 7859883
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated Uveitis.
Groen-Hakan F; Eurelings L; ten Berge JC; van Laar J; Ramakers CRB; Dik WA; Rothova A
JAMA Ophthalmol; 2017 Dec; 135(12):1352-1358. PubMed ID: 29121154
[TBL] [Abstract][Full Text] [Related]
32. [Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas].
Iaguzhinskaia OE; Lazarev IE; Nikitin EA; Samoĭlova RS; Loginova IV; Gemdzhan EG; Novikov VA; Mamiliaeva ZKh; Pivnik AV
Ter Arkh; 2001; 73(4):45-51. PubMed ID: 11494447
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
[TBL] [Abstract][Full Text] [Related]
34. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
[TBL] [Abstract][Full Text] [Related]
35. High cytokine expression and reduced ovarian reserve in patients with Hodgkin lymphoma or non-Hodgkin lymphoma.
Paradisi R; Vicenti R; Macciocca M; Seracchioli R; Rossi S; Fabbri R
Fertil Steril; 2016 Oct; 106(5):1176-1182. PubMed ID: 27430206
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 receptor levels in non-Hodgkin's lymphoma. Correlation to histological degree of malignancy and presence of constitutional symptoms.
Tangen JM; Abrahamsen AF; Ostenstad B; Bergheim J
Acta Oncol; 1990; 29(5):581-3. PubMed ID: 2206570
[TBL] [Abstract][Full Text] [Related]
37. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
Grutters JC; Fellrath JM; Mulder L; Janssen R; van den Bosch JM; van Velzen-Blad H
Chest; 2003 Jul; 124(1):186-95. PubMed ID: 12853522
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of serum CD44 measurement in malignant lymphoma.
Fukuda Y
Kurume Med J; 2001; 48(1):65-9. PubMed ID: 11402623
[TBL] [Abstract][Full Text] [Related]
39. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.
Kalmanti M; Karamolengou K; Dimitriou H; Tosca A; Vlachonikolis I; Peraki M; Georgoulias V; Kalmantis T
Int J Hematol; 1993 Apr; 57(2):147-52. PubMed ID: 8494993
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
Enblad G; Sundström C; Gronowitz S; Glimelius B
Ann Oncol; 1995 Jan; 6(1):65-70. PubMed ID: 7710984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
